文献速递骨质疏松与代谢性骨病创伤骨科

抗骨质疏松药物预防继发性脆性骨折的有效性:系统综述与荟萃分析

Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis.
PubMed 文献 · Osteoporos Int · 2017-08-02

该系统综述与荟萃分析纳入26项随机对照试验,评估双膦酸盐、选择性雌激素受体调节剂、甲状旁腺激素(PTH)或降钙素预防继发性骨折的效果。抗骨质疏松药物显著降低继发性椎体骨折的风险比(RR 0.38-0.77),双膦酸盐和PTH显著降低继发性非椎体骨折风险(RR分别为0.59和0.64),PTH预防继发性椎体骨折的需治疗人数最少(NNT:56)。作者建议临床医生处方这些药物以预防继发性椎体/非椎体骨折。

要点

  • 抗骨质疏松药物显著降低继发性椎体骨折风险(RR 0.38-0.77)。
  • 双膦酸盐和PTH显著降低继发性非椎体骨折风险(RR 0.59和0.64)。
  • PTH预防继发性椎体骨折的需治疗人数最少(NNT:56)。

核心结论

  • 抗骨质疏松药物在预防继发性椎体骨折方面有效。
  • 双膦酸盐和PTH在预防非椎体骨折方面最有效。
  • 作者建议临床医生处方这些药物以预防继发性椎体/非椎体骨折。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase.com和Cochrane Central Register数据库中的随机对照试验。
  • 纳入26项符合 eligibility 标准的随机对照试验,评估使用抗骨质疏松药物(双膦酸盐、选择性雌激素受体调节剂、PTH或降钙素)时继发性骨折的发生率。

主要发现

  • 使用抗骨质疏松药物后,继发性椎体骨折的风险比显著降低(RR 0.38-0.77)。
  • 双膦酸盐和PTH显著降低继发性非椎体骨折风险(RR 0.59和0.64)。
  • PTH预防继发性椎体骨折的需治疗人数最少(NNT:56)。

关键数值与推荐

  • 继发性椎体骨折:抗骨质疏松药物使RR显著降低至0.38-0.77。
  • 继发性非椎体骨折:双膦酸盐RR 0.59,PTH RR 0.64,均显著降低风险。
  • PTH预防继发性椎体骨折的NNT为56。

临床怎么用

  • 作者建议临床医生应处方抗骨质疏松药物以预防继发性椎体/非椎体骨折。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with osteoporotic fractures have an increased risk for secondary fractures. However, a rigorous study that assesses the effectiveness of individual osteoporotic drugs in preventing subsequent fractures is lacking. The purpose of this review was to analyze the effectiveness of anti-osteoporotic drugs in preventing secondary fractures. We searched for randomized controlled trials that showed the incidence of secondary fractures while using anti-osteoporotic drugs (bisphosphonates, selective estrogen receptor modulators, parathyroid hormone (PTH), or calcitonin) in MEDLINE, Embase.com , and Cochrane Central Register databases. We estimated risk ratios (RR) and numbers needed to treat (NNT) to prevent secondary fractures. Twenty-six studies met our eligibility criteria. There was a significant reduction in RR (0.38-0.77) after the use of anti-osteoporotic drugs for secondary vertebral fractures. Bisphosphonates and PTH significantly reduced the risk of a secondary non-vertebral fracture (RR 0.59 and 0.64). PTH needed the fewest number of patients to be treated to prevent a secondary vertebral fracture (NNT: 56). Our study demonstrated the effectiveness of anti-osteoporotic agents included in our systematic review in preventing secondary vertebral fractures. Bisphosphonates and PTH were most effective in preventing non-vertebral fractures. We suggest that clinicians should prescribe these drugs to prevent secondary vertebral/non-vertebral fractures.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Saito T, Sterbenz JM, Malay S, et al. Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis. Osteoporos Int. 2017. PMID: 28770272. doi:10.1007/s00198-017-4175-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。